-
-
-
-
-
-
-
Xeris Pharmaceuticals Inc. (XERS) Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous Levothyroxine (XP-8121)
-
-
-
-
-
-
-
Citius Pharmaceuticals (CTXR) Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
-
-
-
-
-
-
-
EyePoint (EYPT) Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy Did Not Meet its Primary Endpoint
-
-
-
-
-
-
-
Inspire Medical (INSP), ResMed (RMD) on Watch Following Report on Sleep Apnea
-
-
-
-
-
-
-
YS Biopharma (YS) Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
-
-
-
-
-
-
-
Macrogenics (MGNX) Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
-
-
-
-
-
-
-
Moderna (MRNA) Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
-
5,528 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving Hot FDA News reports.